Clear Street raised the firm's price target on Trevi Therapeutics to $29 from $21 and keeps a Buy rating on the shares. The company's key opinion leader event has strengthened the firm's conviction in Haduvio's potential to address the chronic-cough market, the analyst tells investors in a research note.
